Opportunity Information: Apply for PAR 25 072
The National Cancer Institute (NCI), part of the National Institutes of Health, is offering a cooperative agreement funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)" (Funding Opportunity Number: PAR-25-072; CFDA: 93.399). The central aim is to speed up the development and real-world testing of evidence-based cancer interventions that can improve health equity and better represent the full diversity of people, communities, and care settings across the United States. In practice, this means NCI is looking for projects that do not only work in ideal, tightly controlled research environments, but that can demonstrate impact in routine clinical and community conditions where patients actually receive care and support.
This opportunity specifically supports pragmatic clinical trials that evaluate cancer-related interventions across the cancer control continuum. The "cancer control continuum" spans many stages and settings, such as prevention, screening and early detection, diagnosis, treatment, survivorship, supportive and palliative care, and care delivery strategies that influence outcomes. The interventions can be clinical, behavioral, organizational, or system-level, as long as they are designed to improve cancer-related outcomes and are tested using a pragmatic trial approach. Pragmatic trials generally emphasize broad inclusion, real-world workflows, usual-care comparison conditions when appropriate, and outcomes that matter to patients, communities, health systems, and decision-makers, which aligns with the NOFO's focus on equity and generalizability.
The award uses the UG3/UH3 phased cooperative agreement mechanism, which is structured to move projects from a preparatory phase into full implementation. During the UG3 phase, recipients are expected to refine and optimize the intervention and complete key study start-up activities so the trial can be launched efficiently and rigorously. This includes finalizing protocols and operational plans, confirming partnerships and site readiness, addressing feasibility issues, and completing other trial-readiness steps needed before enrollment and full execution. If UG3 milestones are met, projects transition into the UH3 phase, where the pragmatic trial is conducted and the intervention's impact on cancer-related outcomes is tested in real-world settings. Because this is a cooperative agreement rather than a standard grant, NCI program staff typically have a more active role in project oversight and collaboration, with an emphasis on milestone-driven progress and shared responsibility for successful execution.
Eligibility is broad and includes many types of domestic U.S. organizations and government entities. Eligible applicants include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; Native American tribal governments (federally recognized); Native American tribal organizations (other than federally recognized tribal governments); public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); small businesses; and other eligible organizations. The NOFO also highlights additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, Indian/Native American Tribal Governments (other than federally recognized), and U.S. territories or possessions. Foreign organizations are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible, reinforcing that the funded work is intended to be led and carried out domestically.
Key administrative details included in the listing are that this is a discretionary funding opportunity and the funding instrument is a cooperative agreement. The original application due date is November 17, 2025, and the listing shows a creation date of November 18, 2024. The posted record does not specify an award ceiling or the expected number of awards, indicating applicants should rely on the full NOFO for budget guidance, milestones, and any limits or expectations regarding project scale.
Overall, this opportunity is designed for teams prepared to run equity-centered pragmatic clinical trials of cancer interventions that can be implemented in varied U.S. settings, with a staged UG3 planning/refinement period followed by a UH3 implementation and evaluation period. The emphasis on pragmatic design, diversity of contexts, and health equity suggests NCI is prioritizing projects that can produce actionable evidence for real-world adoption and sustained impact across different populations and systems.Apply for PAR 25 072
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.399.
- This funding opportunity was created on 2024-11-18.
- Applicants must submit their applications by 2025-11-17. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the name of this funding opportunity?
The opportunity is titled "Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)."
Which agency is offering this opportunity?
The National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), is offering this funding opportunity.
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is PAR-25-072.
What is the CFDA number listed for this opportunity?
The listing includes CFDA 93.399.
What type of funding mechanism is used?
This is a cooperative agreement.
Is this opportunity discretionary or mandatory?
The listing describes this as a discretionary funding opportunity.
What is the overall goal of this program?
The central aim is to speed up the development and real-world testing of evidence-based cancer interventions that can improve health equity and better represent the full diversity of people, communities, and care settings across the United States.
What kind of studies does NCI want to fund under this NOFO?
NCI is seeking pragmatic clinical trials that evaluate cancer-related interventions across the cancer control continuum, with an emphasis on testing impact in routine clinical and community conditions (not only tightly controlled research settings).
What does "pragmatic trial" mean in the context of this opportunity?
In this opportunity, pragmatic trials generally emphasize broad inclusion, real-world workflows, usual-care comparison conditions when appropriate, and outcomes that matter to patients, communities, health systems, and decision-makers. This aligns with the NOFO's focus on equity and generalizability.
What is meant by the "cancer control continuum"?
The cancer control continuum spans multiple stages and settings, including prevention, screening and early detection, diagnosis, treatment, survivorship, supportive and palliative care, and care delivery strategies that influence outcomes.
What types of interventions are allowed?
Interventions may be clinical, behavioral, organizational, or system-level, as long as they are designed to improve cancer-related outcomes and are tested using a pragmatic trial approach.
Does this opportunity require a clinical trial?
Yes. The title explicitly states "Clinical Trial Required," and the opportunity supports pragmatic clinical trials.
What does UG3/UH3 mean?
UG3/UH3 is a phased cooperative agreement mechanism designed to move projects from a preparatory phase (UG3) into full implementation (UH3).
What happens during the UG3 phase?
During UG3, recipients are expected to refine and optimize the intervention and complete key study start-up activities so the trial can be launched efficiently and rigorously. Examples of UG3 activities described include finalizing protocols and operational plans, confirming partnerships and site readiness, addressing feasibility issues, and completing other trial-readiness steps needed before enrollment and full execution.
What happens during the UH3 phase?
If UG3 milestones are met, projects transition to UH3. During UH3, the pragmatic trial is conducted and the intervention's impact on cancer-related outcomes is tested in real-world settings.
Is transition from UG3 to UH3 automatic?
No. The listing indicates that transition occurs if UG3 milestones are met, reflecting a milestone-driven, phased approach.
How is a cooperative agreement different from a standard grant in this program?
Because this is a cooperative agreement, NCI program staff typically have a more active role in project oversight and collaboration, with an emphasis on milestone-driven progress and shared responsibility for successful execution.
Who is eligible to apply?
Eligibility is broad and includes many types of domestic U.S. organizations and government entities. The eligible applicant types listed include:
- State, county, city or township, and special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Native American tribal governments (federally recognized)
- Native American tribal organizations (other than federally recognized tribal governments)
- Public housing authorities/Indian housing authorities
- Nonprofits with or without 501(c)(3) status (other than institutions of higher education)
- For-profit organizations (other than small businesses)
- Small businesses
- Other eligible organizations
Are there additional applicant types specifically highlighted as eligible?
Yes. The listing highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); faith-based or community-based organizations; regional organizations; eligible federal agencies; Indian/Native American Tribal Governments (other than federally recognized); and U.S. territories or possessions.
Are foreign organizations eligible to apply?
No. Foreign organizations are not eligible to apply.
Are non-U.S. components of U.S. organizations eligible?
No. Non-U.S. components of U.S. organizations are not eligible.
When is the application due?
The original application due date listed is November 17, 2025.
What is the listing creation date?
The listing shows a creation date of November 18, 2024.
Does the listing specify an award ceiling or the expected number of awards?
No. The posted record does not specify an award ceiling or the expected number of awards. Applicants are directed (by implication in the listing) to rely on the full NOFO for budget guidance, milestones, and any limits or expectations regarding project scale.
What kinds of settings are these trials expected to be conducted in?
The opportunity emphasizes testing interventions in real-world settings, including routine clinical and community conditions where patients actually receive care and support, and across varied U.S. care settings and communities.
How does the opportunity address health equity?
The NOFO emphasizes health equity and generalizability by prioritizing pragmatic trials that better represent the full diversity of people, communities, and care settings in the United States and that generate actionable evidence for real-world adoption and sustained impact.
What is the main expectation of applicants in terms of project readiness and execution?
Applicants should be prepared for a staged process: completing UG3 trial-readiness work (such as protocol finalization, site readiness, and feasibility) and then, if milestones are met, moving into UH3 to conduct the pragmatic trial and evaluate cancer-related outcomes in real-world conditions, with active NCI involvement typical of a cooperative agreement.
Browse more opportunities from the same category: Education, Health
Next opportunity: Data Integration, Systems, and Quality Technical Assistance (DISQ)
Previous opportunity: U.S. Ambassadors Fund for Cultural Preservation Grants Program
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 25 072
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 25 072) also looked into and applied for these:
| Funding Opportunity |
|---|
| Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional) Apply for PAR 25 094 Funding Number: PAR 25 094 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed) Apply for PAR 24 316 Funding Number: PAR 24 316 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) Apply for PAR 25 204 Funding Number: PAR 25 204 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional) Apply for PAR 25 152 Funding Number: PAR 25 152 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed) Apply for PAR 25 244 Funding Number: PAR 25 244 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed) Apply for PAR 25 243 Funding Number: PAR 25 243 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Investigator Initiated Innovation in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed) Apply for PAR 25 229 Funding Number: PAR 25 229 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Investigator Initiated Innovation in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed) Apply for PAR 25 228 Funding Number: PAR 25 228 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) Apply for PAR 25 096 Funding Number: PAR 25 096 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) Apply for PAR 25 095 Funding Number: PAR 25 095 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| NCMRR Early Career Research Award (R03 Clinical Trial Optional) Apply for PAR 25 124 Funding Number: PAR 25 124 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed) Apply for PAR 25 070 Funding Number: PAR 25 070 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) Apply for PAR 25 069 Funding Number: PAR 25 069 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advancing Genomic Medicine Research (R21 Clinical Trial Optional) Apply for RFA HG 25 003 Funding Number: RFA HG 25 003 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed) Apply for PAR 25 275 Funding Number: PAR 25 275 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advancing Genomic Medicine Research (R01 Clinical Trial Optional) Apply for RFA HG 25 002 Funding Number: RFA HG 25 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Biology of Bladder Cancer (R01 Clinical Trial Optional) Apply for PAR 25 129 Funding Number: PAR 25 129 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Biology of Bladder Cancer (R21 Clinical Trial Optional) Apply for PAR 25 128 Funding Number: PAR 25 128 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed) Apply for RFA DA 26 034 Funding Number: RFA DA 26 034 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| NCI Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed) Apply for PAR 25 135 Funding Number: PAR 25 135 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 25 072", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.